6. Rozen-Zvi B, Yahav D, Gheorghiade M, et al.Vasopressin receptor antagonists for the treatment of hyponatremia:systematic review and meta-analysis.Am J Kid Dis, 2010, 56:325-337.
[2]
7. U.S.Food and Drug Administation.FDA Drug Safety Communication:FDA limits duration and usage of Samsca (tolvaptan) due to possible liver injury leading to organ transplant or death.2013.Available:http://www.fda.gov/downloads/Drugs/DrugSafety/UCM350084.pdf.
[3]
1. Spasovski G, Vanholder1 R, Allolio B, et al.Clinical practice guideline on diagnosis and treatment of hyponatraemia.Eur J Endocrinol, 2014, 170:G1-G47.
[4]
2. Fenske W, Stork S, Koschker AC, et al.Value of fractional uric acid excretion in differential diagnosis of hyponatremic patients on diuretics.J Clin Endocrinol Metab, 2008, 93:2991-2997.
[5]
3. Musch W, Decaux G.Utility and limitations of biochemical parameters in the evaluation of hyponatremia in the elderly.Intern Uro Nephrol, 2001, 32:475-493.
[6]
4. Mohmand HK, Issa D, Ahmad Z, et al.Hypertonic saline for hyponatremia:risk of inadvertent overcorrection.Clin J Am Soc Nephrol, 2007, 2:1110-1117.
[7]
5. Pietrini V, Mozzani F, Crafa P, et al.Central pontine and extrapontine myelinolysis despite careful correction of hyponatremia:clinical and neuropathological findings of a case.Neurol Sci, 2010, 31:227-230.
